Revyve raises €24M to scale yeast egg-replacements

Revyve has announced a Series B financing round of nearly €24 million to accelerate commercial rollout and scale production of functional yeast proteins that replace eggs and additives.

• Main announcement: Revyve raised nearly €24 million in a Series B co-led by ABN AMRO Sustainable Impact Fund and Invest-NL, with support from Brabantse Ontwikkelings Maatschappij (BOM), Danstar Ferment (Lallemand Bio-Ingredients), Grey Silo Ventures, and follow-on participation from Oost NL and Royal Cosun; the funding will be used to modularly scale production and expand commercial rollout to additional food categories and larger global customers, increasing output to over 1,600 tons per year at its Dinteloord facility.
• Background & details: Revyve commissioned a FOAK production site in Dinteloord, Netherlands in 2024 (currently running at capacity for several customers); the company serves customers across Europe, UK, USA, Canada, Mexico and Australia; planned industry appearances this autumn include:
  • Anuga — 4-8 October, Cologne, Hall 01.2 | Stand D028g-E029g (showcase latest applications)
  • Food ingredients Europe — 2-4 December, Paris, Stand #73J23 (showcase latest applications and partnerships)